IMR Press / FBL / Volume 13 / Issue 5 / DOI: 10.2741/2815

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Cancer targeting using tumor suppressor genes
Show Less
1 Department of Clinical Research and Development, Introgen Research Institute, Introgen Therapeutics Inc. and Department of Thoracic and Cardiovascular Surgery, the University of Texas, MD Anderson Cancer Center, Houston, USA

*Author to whom correspondence should be addressed.

 

Front. Biosci. (Landmark Ed) 2008, 13(5), 1959–1967; https://doi.org/10.2741/2815
Published: 1 January 2008
Abstract

Conventional cancer treatments include cytotoxic chemotherapies and radiotherapy, which result in significant collateral toxicities. The goal for future cancer treatments is to leverage improved understanding of cancer biology mechanisms and thereby develop targeted drugs that display exquisite tumor selectivity and avoid iatrogenic damage. In this review, we discuss the potential of tumor suppressor genes for development of cancer-selective drugs using the tumor suppressor p53 as an archetype.

Share
Back to top